Literature DB >> 21917891

Vaccine-induced cross-genotype reactive neutralizing antibodies against hepatitis C virus.

Jean-Christophe Meunier1, Judith M Gottwein, Michael Houghton, Rodney S Russell, Suzanne U Emerson, Jens Bukh, Robert H Purcell.   

Abstract

We detected cross-reactive neutralizing antibodies (NtAb) against hepatitis C virus (HCV) in chimpanzees vaccinated with HCV-1 (genotype 1a) recombinant E1/E2 envelope glycoproteins. Five vaccinated chimpanzees, protected following HCV-1 challenge, were initially studied using the heterologous H77 (genotype 1a) HCVpp assay. All animals had developed NtAb after the second vaccination; 4 animals had reciprocal titers of ≥200 at the time of challenge. Using genotypes 1a-6a HCV pseudoparticles (HCVpp) and cell culture-derived HCV (HCVcc) assays, cross-reactive NtAb were detected against 1a, 4a, 5a, and 6a, with limited reactivity against 2a and 3a. Our study provides encouragement for the development of a recombinant envelope-based vaccine against hepatitis C.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21917891      PMCID: PMC3203383          DOI: 10.1093/infdis/jir511

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  14 in total

1.  Characterization of the hepatitis C virus E2/NS1 gene product expressed in mammalian cells.

Authors:  R R Spaete; D Alexander; M E Rugroden; Q L Choo; K Berger; K Crawford; C Kuo; S Leng; C Lee; R Ralston
Journal:  Virology       Date:  1992-06       Impact factor: 3.616

2.  Incidence of hepatitis C in patients receiving different preparations of hepatitis B immunoglobulins after liver transplantation.

Authors:  C Féray; M Gigou; D Samuel; B Ducot; P Maisonneuve; M Reynès; A Bismuth; H Bismuth
Journal:  Ann Intern Med       Date:  1998-05-15       Impact factor: 25.391

3.  Evidence for cross-genotype neutralization of hepatitis C virus pseudo-particles and enhancement of infectivity by apolipoprotein C1.

Authors:  Jean-Christophe Meunier; Ronald E Engle; Kristina Faulk; Ming Zhao; Birke Bartosch; Harvey Alter; Suzanne U Emerson; Francois-Loic Cosset; Robert H Purcell; Jens Bukh
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-14       Impact factor: 11.205

4.  Novel infectious cDNA clones of hepatitis C virus genotype 3a (strain S52) and 4a (strain ED43): genetic analyses and in vivo pathogenesis studies.

Authors:  Judith M Gottwein; Troels K H Scheel; Benoit Callendret; Yi-Ping Li; Heather B Eccleston; Ronald E Engle; Sugantha Govindarajan; William Satterfield; Robert H Purcell; Christopher M Walker; Jens Bukh
Journal:  J Virol       Date:  2010-03-03       Impact factor: 5.103

Review 5.  Prospects for prophylactic and therapeutic vaccines against the hepatitis C viruses.

Authors:  Michael Houghton
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

6.  Current status of a hepatitis C vaccine: encouraging results but significant challenges ahead.

Authors:  Marianne Mikkelsen; Jens Bukh
Journal:  Curr Infect Dis Rep       Date:  2007-03       Impact factor: 3.725

7.  Characterization of the envelope glycoproteins associated with infectious hepatitis C virus.

Authors:  Gabrielle Vieyres; Xavier Thomas; Véronique Descamps; Gilles Duverlie; Arvind H Patel; Jean Dubuisson
Journal:  J Virol       Date:  2010-07-28       Impact factor: 5.103

8.  Efficacy of prophylactic gamma-globulin in preventing non-A, non-B post-transfusion hepatitis.

Authors:  R G Knodell; M E Conrad; A L Ginsberg; C J Bell
Journal:  Lancet       Date:  1976-03-13       Impact factor: 79.321

9.  Vaccination of chimpanzees against infection by the hepatitis C virus.

Authors:  Q L Choo; G Kuo; R Ralston; A Weiner; D Chien; G Van Nest; J Han; K Berger; K Thudium; C Kuo
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-15       Impact factor: 11.205

10.  Induction of broad CD4+ and CD8+ T-cell responses and cross-neutralizing antibodies against hepatitis C virus by vaccination with Th1-adjuvanted polypeptides followed by defective alphaviral particles expressing envelope glycoproteins gpE1 and gpE2 and nonstructural proteins 3, 4, and 5.

Authors:  Yinling Lin; Taewoo Kwon; John Polo; Yi-Fei Zhu; Stephen Coates; Kevin Crawford; Christine Dong; Mark Wininger; John Hall; Mark Selby; Doris Coit; Angelica Medina-Selby; Colin McCoin; Philip Ng; Debbie Drane; David Chien; Jang Han; Michael Vajdy; Michael Houghton
Journal:  J Virol       Date:  2008-05-28       Impact factor: 5.103

View more
  53 in total

1.  Hepatitis C virus epitope exposure and neutralization by antibodies is affected by time and temperature.

Authors:  Michelle C Sabo; Vincent C Luca; Stuart C Ray; Jens Bukh; Daved H Fremont; Michael S Diamond
Journal:  Virology       Date:  2011-11-12       Impact factor: 3.616

2.  Will there be a vaccine to protect against the hepatitis C virus?

Authors:  Benoît Callendret; Christopher M Walker
Journal:  Gastroenterology       Date:  2012-05       Impact factor: 22.682

Review 3.  Immune mechanisms of vaccine induced protection against chronic hepatitis C virus infection in chimpanzees.

Authors:  Babs E Verstrepen; André Boonstra; Gerrit Koopman
Journal:  World J Hepatol       Date:  2015-01-27

4.  Native Folding of a Recombinant gpE1/gpE2 Heterodimer Vaccine Antigen from a Precursor Protein Fused with Fc IgG.

Authors:  Michael Logan; John Law; Jason Alexander Ji-Xhin Wong; Darren Hockman; Amir Landi; Chao Chen; Kevin Crawford; Juthika Kundu; Lesley Baldwin; Janelle Johnson; Anita Dahiya; Gerald LaChance; Joseph Marcotrigiano; Mansun Law; Steven Foung; Lorne Tyrrell; Michael Houghton
Journal:  J Virol       Date:  2016-12-16       Impact factor: 5.103

Review 5.  Hepatitis C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy.

Authors:  Filippo Ansaldi; Andrea Orsi; Laura Sticchi; Bianca Bruzzone; Giancarlo Icardi
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

Review 6.  Current progress in development of hepatitis C virus vaccines.

Authors:  T Jake Liang
Journal:  Nat Med       Date:  2013-07       Impact factor: 53.440

7.  Recombinant hepatitis C virus envelope glycoprotein vaccine elicits antibodies targeting multiple epitopes on the envelope glycoproteins associated with broad cross-neutralization.

Authors:  Jason Alexander Ji-Xhin Wong; Rakesh Bhat; Darren Hockman; Michael Logan; Chao Chen; Aviad Levin; Sharon E Frey; Robert B Belshe; D Lorne Tyrrell; John Lok Man Law; Michael Houghton
Journal:  J Virol       Date:  2014-10-01       Impact factor: 5.103

Review 8.  Will there be a vaccine to prevent HCV infection?

Authors:  Jonathan R Honegger; Yan Zhou; Christopher M Walker
Journal:  Semin Liver Dis       Date:  2014-04-29       Impact factor: 6.115

9.  The missing pieces of the HCV entry puzzle.

Authors:  Sarah C Ogden; Hengli Tang
Journal:  Future Virol       Date:  2015       Impact factor: 1.831

10.  Fine mapping of murine antibody responses to immunization with a novel soluble form of hepatitis C virus envelope glycoprotein complex.

Authors:  Tinashe B Ruwona; Erick Giang; Travis Nieusma; Mansun Law
Journal:  J Virol       Date:  2014-06-25       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.